Asunto(s)
Enfermedad Crónica/terapia , Conductas Relacionadas con la Salud , Medicina Integrativa/organización & administración , Farmacéuticos/organización & administración , Rol Profesional , Enfermedad Crónica/epidemiología , Atención a la Salud/organización & administración , Epidemias , Humanos , Atención Dirigida al Paciente/organización & administración , Calidad de la Atención de Salud/organización & administración , Estados Unidos/epidemiologíaRESUMEN
This article presents the results of a previously unexplored aspect of qualitative leg ulcer research. The study has examined the lived experience and cultural illness explanations of a sample of British-Indian patients living with leg and foot ulceration. Semi-structured interviews were used to collect data from 16 Indian patients drawn from leg ulcer clinics and district nursing lists in Ealing Primary Care Trust and Hounslow Primary Care Trust. Eight respondents had venous ulceration, seven were diabetic and had ulcers of arterial aetiology, and one had ulceration due to lymphoedema. Popular perceptions of the cause of leg ulceration were influenced by the humoral theories of balance and imbalance. Other explanations included poor circulation, lowered immunity, bad blood, being cursed and doing something wrong in a past life or this life.
Asunto(s)
Actitud Frente a la Salud/etnología , Conductas Relacionadas con la Salud/etnología , Conocimientos, Actitudes y Práctica en Salud , Úlcera de la Pierna/etnología , Adaptación Psicológica , Adulto , Anciano , Anciano de 80 o más Años , Causalidad , Diversidad Cultural , Femenino , Homeopatía , Humanos , India/etnología , Úlcera de la Pierna/etiología , Úlcera de la Pierna/prevención & control , Masculino , Medicina Ayurvédica , Medicina Unani , Persona de Mediana Edad , Narración , Investigación Metodológica en Enfermería , Investigación Cualitativa , Calidad de Vida/psicología , Autocuidado/métodos , Autocuidado/psicología , Encuestas y Cuestionarios , YogaRESUMEN
Here, we describe the preclinical pharmacological profile of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel, chirally pure inhaled beta(2) adrenoceptor agonist, in comparison with marketed drugs. Indacaterol is close to a full agonist at the human beta(2) adrenoceptor (E(max) = 73 +/- 1% of the maximal effect of isoprenaline; pEC(50) = 8.06 +/- 0.02), whereas salmeterol displays only partial efficacy (38 +/- 1%). The functional selectivity profile of indacaterol over beta(1) human adrenoceptors is similar to that of formoterol, whereas its beta(3) adrenoceptor selectivity profile is similar to that of formoterol and salbutamol. In isolated superfused guinea pig trachea, indacaterol has a fast onset of action (30 +/- 4 min) similar to formoterol and salbutamol, and a long duration of action (529 +/- 99 min) comparable with salmeterol. In the conscious guinea pig, when given intratracheally as a dry powder, indacaterol inhibits 5-hydroxytryptamine-induced bronchoconstriction for at least 24 h, whereas salmeterol, formoterol, and salbutamol have durations of action of 12, 4, and 2 h, respectively. When given via nebulization to anesthetized rhesus monkeys, all of the compounds dose-dependently inhibit methacholine-induced bronchoconstriction, although indacaterol produces the most prolonged bronchoprotective effect and induces the lowest increase in heart rate for a similar degree of antibronchoconstrictor activity. In conclusion, the preclinical profile of indacaterol suggests that this compound has a superior duration of action compatible with once-daily dosing in human, together with a fast onset of action and an improved cardiovascular safety profile over marketed inhaled beta(2) adrenoceptor agonists.